Novel systemic therapy in advanced non-small-cell lung cancer
Standard chemotherapy regimes (platinum-based combinations) for advanced non-small-cell lung cancer have reached their therapeutic limits. In the last few years standard chemotherapy has been supplemented by targeted therapy. Targeted therapy consists of tyrosine kinase inhibitors (TKIs) against epi...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Hamdan Medical Journal |
Online Access: | http://www.hamdanjournal.org/article.asp?issn=2227-2437;year=2016;volume=9;issue=1;spage=39;epage=56;aulast=Tiut;type=0 |
id |
doaj-4b96a525287447c1950960147cb5f955 |
---|---|
record_format |
Article |
spelling |
doaj-4b96a525287447c1950960147cb5f9552020-12-02T12:41:03ZengWolters Kluwer Medknow PublicationsHamdan Medical Journal2227-24372227-247X2016-01-0191395610.7707/hmj.615Novel systemic therapy in advanced non-small-cell lung cancerCristina TiutChristoph C ZielinskiStandard chemotherapy regimes (platinum-based combinations) for advanced non-small-cell lung cancer have reached their therapeutic limits. In the last few years standard chemotherapy has been supplemented by targeted therapy. Targeted therapy consists of tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) mutation-positive tumours or ALK (anaplastic lymphoma kinase)-rearranged tumours as well as antiangiogenic TKIs and monoclonal antibodies directed against vascular endothelial growth factor, vascular endothelial growth factor receptor 2 or EGFR. Although targeted therapy has made remarkable progress, there is great hope for the use of immune checkpoint inhibitors, which specifically enhance the immune response directed against the tumour.http://www.hamdanjournal.org/article.asp?issn=2227-2437;year=2016;volume=9;issue=1;spage=39;epage=56;aulast=Tiut;type=0 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cristina Tiut Christoph C Zielinski |
spellingShingle |
Cristina Tiut Christoph C Zielinski Novel systemic therapy in advanced non-small-cell lung cancer Hamdan Medical Journal |
author_facet |
Cristina Tiut Christoph C Zielinski |
author_sort |
Cristina Tiut |
title |
Novel systemic therapy in advanced non-small-cell lung cancer |
title_short |
Novel systemic therapy in advanced non-small-cell lung cancer |
title_full |
Novel systemic therapy in advanced non-small-cell lung cancer |
title_fullStr |
Novel systemic therapy in advanced non-small-cell lung cancer |
title_full_unstemmed |
Novel systemic therapy in advanced non-small-cell lung cancer |
title_sort |
novel systemic therapy in advanced non-small-cell lung cancer |
publisher |
Wolters Kluwer Medknow Publications |
series |
Hamdan Medical Journal |
issn |
2227-2437 2227-247X |
publishDate |
2016-01-01 |
description |
Standard chemotherapy regimes (platinum-based combinations) for advanced non-small-cell lung cancer have reached their therapeutic limits. In the last few years standard chemotherapy has been supplemented by targeted therapy. Targeted therapy consists of tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) mutation-positive tumours or ALK (anaplastic lymphoma kinase)-rearranged tumours as well as antiangiogenic TKIs and monoclonal antibodies directed against vascular endothelial growth factor, vascular endothelial growth factor receptor 2 or EGFR. Although targeted therapy has made remarkable progress, there is great hope for the use of immune checkpoint inhibitors, which specifically enhance the immune response directed against the tumour. |
url |
http://www.hamdanjournal.org/article.asp?issn=2227-2437;year=2016;volume=9;issue=1;spage=39;epage=56;aulast=Tiut;type=0 |
work_keys_str_mv |
AT cristinatiut novelsystemictherapyinadvancednonsmallcelllungcancer AT christophczielinski novelsystemictherapyinadvancednonsmallcelllungcancer |
_version_ |
1724406646810083328 |